(VIANEWS) – Shares of INVENTIVA (CAC 40: IVA.PA) fell by a staggering 31.75% in 21 sessions from €3.15 to €2.15 at 14:53 EST on Wednesday, after three sequential sessions in a row of gains. CAC 40 is jumping 0.45% to €7,416.66, following the last session’s downward trend.
About INVENTIVA
Inventiva S.A., a clinical-stage biopharmaceutical company, focuses on the development of oral small molecule therapies for the treatment of non-alcoholic steatohepatitis (NASH) and other diseases. Its lead product candidate is Lanifibranor, which is in Phase III clinical trial to treat NASH. The company also develops Odiparcil, which has completed Phase IIa clinical trial for the treatment of mucopolysaccharidoses type VI disease. In addition, it has a pipeline of earlier stage programs in oncology and other diseases. The company was founded in 2011 and is headquartered in Daix, France.
Earnings Per Share
As for profitability, INVENTIVA has a trailing twelve months EPS of €-1.17.
Volatility
INVENTIVA’s last week, last month’s, and last quarter’s current intraday variation average was a positive 1.73%, a negative 2.13%, and a positive 2.57%.
INVENTIVA’s highest amplitude of average volatility was 1.73% (last week), 3.06% (last month), and 2.57% (last quarter).
Stock Price Classification
According to the stochastic oscillator, a useful indicator of overbought and oversold conditions, INVENTIVA’s stock is considered to be oversold (<=20).
Volume
Today’s last reported volume for INVENTIVA is 35121 which is 48.65% below its average volume of 54071.
More news about INVENTIVA (IVA.PA).
